Author: Falzarano, Darryl; de Wit, Emmie; Martellaro, Cynthia; Callison, Julie; Munster, Vincent J.; Feldmann, Heinz
Title: Inhibition of novel ß coronavirus replication by a combination of interferon-a2b and ribavirin Document date: 2013_4_18
ID: tgngoea8_2
Snippet: Despite limited information on this new virus, it has been determined that in contrast to SARS-CoV, which uses angiotensin-converting enzyme 2 (ACE2) to gain entry into cells 9,10 , nCoV uses dipeptidyl peptidase 4 (DPP4 or CD26) as a functional receptor 11 . This finding may be important as the requirement for ACE2 was thought to be partially responsible for the pathogenicity of SARS-CoV, while also serving as one of the factors that may have li.....
Document: Despite limited information on this new virus, it has been determined that in contrast to SARS-CoV, which uses angiotensin-converting enzyme 2 (ACE2) to gain entry into cells 9,10 , nCoV uses dipeptidyl peptidase 4 (DPP4 or CD26) as a functional receptor 11 . This finding may be important as the requirement for ACE2 was thought to be partially responsible for the pathogenicity of SARS-CoV, while also serving as one of the factors that may have limited spread from human-to-human. As the pathogenesis of nCoV could be significantly different from previously studied coronaviruses, the ability to predict whether this virus is likely to result in a larger epidemic or even pandemic, such as occurred with SARS-CoV, is unknown.
Search related documents:
Co phrase search for related documents- angiotensin convert and cell entry gain: 1
- angiotensin convert and dipeptidyl peptidase: 1
- angiotensin convert enzyme and dipeptidyl peptidase: 1
- cell entry and dipeptidyl peptidase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- cell entry and functional receptor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32
- cell entry and human human: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59
- cell entry and human human spread: 1, 2
- cell entry and limited information: 1, 2, 3, 4, 5, 6
- cell entry and nCoV pathogenesis: 1
- cell entry and new virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- cell entry and previously study: 1, 2, 3, 4, 5, 6
- cell entry and SARS CoV occur: 1, 2
- cell entry and SARS CoV pathogenicity: 1, 2, 3, 4, 5, 6, 7, 8
- cell entry gain and dipeptidyl peptidase: 1, 2
- cell entry gain and human human: 1
- cell entry gain and SARS CoV pathogenicity: 1
- dipeptidyl peptidase and functional receptor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- dipeptidyl peptidase and human human: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- dipeptidyl peptidase and human human spread: 1
Co phrase search for related documents, hyperlinks ordered by date